Hydromer, Inc. (OTC: HYDI), a pioneer in coating technologies for medical devices, has disclosed its preliminary, unaudited financial results for the quarter ended June 30, 2025. The company reported a revenue of $0.94 million, marking a 14% increase from the $0.82 million recorded in the same quarter the previous year. However, Hydromer faced a net loss of $38,000, attributed to legal and professional expenses, alongside costs related to facility and equipment upgrades.
Michael E. Torti, CEO of Hydromer, emphasized the company's resilience and strategic direction. 'This quarter reflects both the resilience of our core business and the deliberate steps we are taking to position Hydromer for sustainable, long-term growth,' Torti stated. He further noted that the revenue growth underscores the strength of customer relationships and the value of Hydromer's coating technologies in the medical device industry. Despite the net loss, Torti views the incurred expenses as strategic investments aimed at fostering innovation, expanding market reach, and enhancing financial performance in the forthcoming quarters.
Hydromer's commitment to innovation and operational efficiency remains unwavering. The company is focused on advancing its product pipeline, establishing new partnerships, and maintaining disciplined execution to achieve its long-term objectives. With over four decades of expertise in surface modification and coating solutions, Hydromer continues to serve a global clientele, adhering to stringent quality standards such as Good Manufacturing Practice (GMP) and International Organization for Standardization (ISO) certifications.
The preliminary financial results are subject to the completion of Hydromer's 2025 year-end financial reporting processes, including reviews and audit, which may lead to adjustments. The company cautions that forward-looking statements involve risks and uncertainties, and actual outcomes may differ materially from current expectations. For more information, visit https://www.hydromer.com.
